ARGX is argenx SE (Healthcare) — a non-dividend-paying stock. Trading at $1033.15. Market cap: $64.63B.
Stock snapshot
| Price | $1033.15 |
| Market cap | $64.63B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About ARGX
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Related non-dividend companies
Other non-dividend stocks investors research alongside ARGX. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is ARGX's current stock price?
ARGX (argenx SE) is currently trading at $1033.15.
Does ARGX pay a dividend?
ARGX (argenx SE) does not currently pay a regular dividend.
Track ARGX in DiviDrip
Add ARGX to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search ARGX and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-06. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.